Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00014495 · ClinicalTrials.gov registry record · Phase 1
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00014495: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00014495 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00014495, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of combining chemotherapy and monoclonal antibody therapy in treating patients who have advanced myeloid cancer.
Interventions
- BIOLOGICAL filgrastim
- DRUG cytarabine
- RADIATION bismuth Bi213 monoclonal antibody M195
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2000-11 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00014495
The ClinicalTrials.gov registry entry for NCT00014495 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which filgrastim is the first listed.
NCT00014495 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00014495 about?
NCT00014495 is a clinical study titled "Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of combining chemotherapy and monoclonal ...
What is the current status of trial NCT00014495?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2000-11. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00014495?
The interventions under investigation include: filgrastim (BIOLOGICAL), cytarabine (DRUG), bismuth Bi213 monoclonal antibody M195 (RADIATION).
Who is sponsoring clinical trial NCT00014495?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.